2011

1. Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.

   Clinical lymphoma, myeloma & leukemia, Vol. 11, Núm. 1, pp. 168-171